Advertisement
Advertisement
FHTX
Foghorn Therapeutics Inc. Common Stock
3.87
USDSponsored
-0.37
-8.73%
Sep 23, 16:00 UTC -4
Closed
After-Market
3.99
+0.12
+3.13%
FHTX Earnings Reports
Positive Surprise Ratio
FHTX beat 16 of 24 last estimates.
67%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$7.23M
/-$0.24
Implied change from Q2 26 (Revenue/ EPS)
-55.01%
/+140.00%
Implied change from Q3 25 (Revenue/ EPS)
-11.30%
/-4.00%
Foghorn Therapeutics Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, FHTX reported earnings of -0.10 USD per share (EPS) for Q2 26, beating the estimate of -0.26 USD, resulting in a 61.69% surprise. Revenue reached 16.07 million, compared to an expected 6.11 million, with a 162.83% difference. The market reacted with a +14.14% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 7.23 million USD, implying an increase of 140.00% EPS, and decrease of -55.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Foghorn Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Foghorn Therapeutics Inc. Common Stock reported EPS of -$0.10, beating estimates by 61.69%, and revenue of $16.07M, 162.83% above expectations.
How did the market react to Foghorn Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 14.14%, changed from $4.88 before the earnings release to $5.57 the day after.
When is Foghorn Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Foghorn Therapeutics Inc. Common Stock's next earnings report?
Based on 8
analysts, Foghorn Therapeutics Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $7.23M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.